Editing Risk: Gene Targets for Lifelong Cardiovascular Disease Prevention

• Human loss-of-function genetics validates PCSK9, ANGPTL3, APOC3, and LPA as causal targets for cardiovascular risk reduction, providing a natural blueprint for prevention-based therapies.

• In vivo gene editing enables direct and potentially permanent modification of lipid pathways in the liver, shifting cardiovascular care from chronic pharmacology toward one-time biological intervention.

• Early clinical programs demonstrate feasibility but remain in proof-of-concept stages, with long-term durability and safety still under evaluation.

• Delivery technologies and off-target risk are the primary constraints shaping development, making liver accessibility and analytical rigor central to therapeutic design.

• Gene editing reframes cardiovascular medicine as a genetics-guided prevention strategy, rather than a treatment model focused solely on managing established disease.

Hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) are not episodic conditions but lifelong biological risk states driven by inherited and molecular determinants of lipid metabolism. Large human genetic studies have shown that naturally occurring loss-of-function variants in key lipid-regulating genes — including PCSK9, ANGPTL3, APOC3, and LPA — are associated with substantially reduced risk of cardiovascular disease. These findings establish that modifying the activity of specific genes can shift baseline cardiovascular risk over an individual’s lifetime rather than merely treating downstream clinical events.

This genetic evidence has reframed prevention as a problem of target selection rather than solely drug selection. Instead of relying on continuous pharmacologic suppression of lipid pathways, emerging strategies seek to reproduce the protective biology observed in these naturally occurring variants. In this context, gene targets function as durable “risk levers” where altering expression can reshape long-term exposure to atherogenic lipoproteins. The implication is a shift from managing disease trajectories to reengineering the biological drivers that create those trajectories in the first place.

Building directly on this rationale, in vivo genome editing therapies are now being developed to permanently disrupt expression of validated lipid targets in the liver, the central organ of cholesterol and lipoprotein regulation. Multiple early-stage clinical programs are exploring base-editing approaches directed at PCSK9, ANGPTL3, and APOC3, with the explicit goal of producing sustained reductions in circulating lipid biomarkers following a single intervention. These efforts translate population genetics into therapeutic design by treating inherited risk as a modifiable biological substrate.

These developments mark a conceptual departure from chronic cardiovascular pharmacology toward prevention through permanent biological modification. Rather than titrating drugs against evolving disease, gene-editing strategies aim to intervene upstream at the genetic determinants of risk. In this framework, cardiovascular prevention becomes less about managing pathology and more about reshaping the molecular architecture that predisposes individuals to it.

PCSK9 represents the most extensively validated genetic target for lifelong low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular risk modification. Population studies have demonstrated that specific sequence variations in PCSK9 associated with reduced protein function lead to lower circulating LDL-C levels and confer protection against coronary heart disease.¹ This relationship provided one of the earliest and clearest examples that inherited disruption of a single lipid-regulating gene could produce durable, clinically meaningful effects on cardiovascular outcomes.

Beyond isolated variants, entire human populations exist with naturally inactive or markedly reduced PCSK9 function and lifelong low LDL-C. These individuals serve as living models of long-term target inhibition without apparent adverse developmental consequences, offering a form of natural safety and efficacy evidence that extends across decades of exposure.² Such observations have positioned PCSK9 as a benchmark target for translating genetic insight into therapeutic intervention.

In this context, gene-editing strategies aim not to introduce novel biology but to replicate a protective state that already exists in nature. Editing PCSK9 in hepatocytes is conceptually equivalent to recreating these loss-of-function variants in patients who did not inherit them. The approach reframes therapy as an effort to mimic favorable human genetics rather than impose an artificial pharmacologic effect, grounding innovation in long-standing biological precedent.

Genetic validation extends beyond PCSK9 to additional nodes in lipid and lipoprotein metabolism. Loss-of-function variants in ANGPTL3 have been shown to associate with significantly reduced risk of coronary artery disease, reinforcing the concept that modulation of triglyceride-rich lipoproteins and related pathways can influence atherosclerotic risk.^3,4 These findings highlight that cardiovascular protection is not limited to LDL-C alone but can be achieved through multiple biological routes.

Similarly, APOC3 has emerged as a genetically supported target with strong links to triglyceride metabolism and ischemic cardiovascular disease. Individuals carrying loss-of-function mutations in APOC3 exhibit low triglyceride levels and a reduced incidence of ischemic vascular events.^5,6 Together, these data establish that genetic disruption of distinct but interconnected lipid pathways produces convergent protective effects.

This convergence supports a model of multi-target genetic prevention in which several genes can serve as independent yet complementary levers for cardiovascular risk reduction. Rather than a single dominant pathway, lipid biology appears to be regulated by a polygenic architecture in which multiple validated targets offer parallel opportunities for intervention. Gene-editing approaches thus inherit not only one proof of concept but an expanding portfolio of genetically sanctioned targets.

Lipoprotein(a) (Lp(a)) is a genetically determined cardiovascular risk factor that is largely independent of traditional lipid measures. Large population analyses have shown that Lp(a) concentration is dose-dependently associated with coronary artery disease and aortic valve stenosis, underscoring its role as a causal contributor rather than a passive biomarker.⁷ This distinguishes Lp(a) from LDL-C and triglycerides as a separate axis of inherited risk.

Further evidence indicates that genetically lowered Lp(a) levels are associated with reduced risk across multiple cardiovascular phenotypes, including peripheral vascular disease, stroke, and heart failure.8 These associations reinforce the concept that LPA is not merely correlated with disease but actively participates in its development through genetic mechanisms.

Although human clinical gene-editing programs targeting LPA have not yet been established, preclinical studies have demonstrated the feasibility of disrupting the LPA gene in vivo.⁹ These experiments provide an initial technical foundation for considering LPA as a future editing target. In this sense, Lp(a) occupies a frontier position in genetic prevention: a risk factor poorly addressed by existing therapies yet supported by strong genetic causality and emerging experimental tools.

The translation of genetic validation into therapeutic reality is now underway for PCSK9 through first-in-human in vivo gene-editing programs. Clinical trials are actively evaluating base-editing approaches designed to disrupt PCSK9 expression in hepatocytes, directly targeting the liver as the central site of LDL cholesterol regulation.¹⁰ These studies represent a critical inflection point as gene editing advances from theoretical prevention to interventional cardiology.

Early clinical readouts from these programs have provided initial evidence that a single administration can meaningfully reduce circulating PCSK9 protein and LDL-C levels. Interim data presented from early-phase studies reported sustained reductions in both biomarkers following a one-time infusion, supporting the feasibility of durable lipid modification without repeated dosing.^11,12 While these findings remain preliminary, they demonstrate biological activity consistent with the underlying genetic rationale.

Conceptually, these programs embody a one-time intervention model that contrasts sharply with lifelong pharmacotherapy. Rather than requiring continuous drug exposure to suppress PCSK9 activity, base editing seeks to permanently recreate a protective genetic state. This reframes lipid lowering as a prevention-scale therapy, with the potential to alter cumulative cardiovascular risk over decades rather than incrementally managing cholesterol levels over time.

Building on the foundational work in PCSK9, gene-editing pipelines are expanding to additional lipid-regulating targets with strong genetic support. VERVE-201 is being developed as an in vivo base-editing therapy targeting ANGPTL3, extending editing strategies beyond LDL-C toward broader lipoprotein and triglyceride pathways.^13,14 This progression reflects confidence that the underlying editing platform can be adapted across multiple validated targets.

In parallel, CS-121 represents an in vivo base-editing approach directed at APOC3, using lipid nanoparticle delivery to achieve hepatic gene disruption.^15,16 By targeting a gene central to triglyceride metabolism, this program illustrates how gene-editing strategies can address lipid abnormalities that are incompletely managed by existing therapies.

These efforts herald the platformization of cardiovascular gene editing. Rather than developing isolated, target-specific solutions, companies are applying a common technological framework across multiple lipid axes. This approach positions in vivo editing as a modular prevention strategy, capable of addressing diverse but interconnected drivers of cardiovascular risk through precise genetic intervention.

The liver has emerged as the primary entry point for in vivo genome editing therapies aimed at cardiovascular risk reduction because of its central role in lipid metabolism and its accessibility to systemic delivery technologies. Lipid nanoparticles (LNPs) have proven highly effective for transporting genome-editing cargo to hepatocytes, enabling direct modification of genes that regulate circulating lipoproteins. LNP-based systems have been particularly successful for liver-directed in vivo editing, even as extension of these approaches to other organs remains technically challenging.¹⁷

This technical asymmetry has shaped therapeutic strategy. PCSK9, ANGPTL3, and APOC3 are all primarily expressed and regulated in the liver, making them well aligned with existing delivery capabilities. Rather than forcing gene editing into less tractable tissues, current development programs have concentrated on targets that match the strengths of hepatic delivery. In this sense, the organ of action is not incidental but foundational to feasibility.

Refinements in targeting specificity have further strengthened this focus. GalNAc-LNP systems, which exploit hepatocyte-specific uptake mechanisms, have been shown to enable targeted delivery of base-editing therapies to the liver. Preclinical studies demonstrate that these constructs can direct genome-editing payloads to hepatic cells with sufficient efficiency to modify lipid-related genes in vivo.¹⁸ Such advances reinforce the liver as the dominant platform for early cardiovascular gene-editing interventions.

Together, these developments illustrate a central constraint of the field: organ accessibility defines therapeutic feasibility. The success of liver-directed delivery has made prevention-oriented gene editing plausible for lipid disorders, while limitations in delivery to other tissues continue to bound the scope of intervention. In this framework, delivery is not simply a technical detail but the primary bottleneck shaping which genetic targets can realistically be pursued for long-term cardiovascular risk reduction.

The regulatory treatment of in vivo gene editing therapies for cardiovascular prevention is anchored within existing gene therapy frameworks rather than a separate category of products. The FDA has issued formal guidance for human gene therapy products that incorporate genome editing in somatic cells, outlining expectations for development programs and the information required to support investigational new drug (IND) applications.¹⁹ This establishes genome editing as an extension of gene therapy rather than a departure from established regulatory paradigms.

Within this guidance, the agency specifies requirements related to product characterization, manufacturing controls, and safety assessment, reflecting the unique risks associated with permanent modification of human cells. Sponsors are expected to provide detailed data on the design of the editing system, the delivery mechanism, and the potential for unintended biological effects. These requirements reinforce a safety-first development philosophy in which molecular precision and analytical rigor are prerequisites for clinical advancement.

By situating genome editing under gene therapy regulations, the FDA emphasizes continuity rather than novelty. Editing technologies are evaluated through the same lens applied to other advanced biologic products, with particular attention to long-term risk and irreversible biological change. This approach underscores that cardiovascular gene editing, despite its preventive ambition, is subject to the same evidentiary standards as therapies intended to treat established disease.

A defining safety challenge for genome-editing medicinal products is the possibility of off-target genetic modification. Regulatory and scientific assessments recognize off-target toxicity as a major unresolved issue, particularly because unintended edits may carry long-term or latent consequences that are difficult to predict at early stages of development.²⁰ In prevention-oriented applications, where therapies may be administered to otherwise stable individuals, tolerance for uncertainty is inherently lower.

Compounding this challenge is the absence of a universally accepted analytical standard for detecting and quantifying off-target effects. Current methods vary in sensitivity and scope, and no single approach has emerged as a gold standard for comprehensive risk assessment. This creates both a technical and regulatory gap: confidence in safety is constrained by the limits of measurement itself.

These factors elevate the regulatory stakes associated with permanent genetic modification. Unlike conventional pharmacologic therapies, genome editing does not permit dose adjustment or withdrawal once the biological change has occurred. As a result, permanence becomes a central consideration in risk evaluation, and analytical uncertainty directly influences regulatory confidence. In this environment, safety is not only a function of biological design but also of the tools available to observe and verify that design’s consequences.

Together, these considerations frame genome editing for cardiovascular prevention as a domain where regulatory scrutiny and technical capability are tightly intertwined. Measurement defines confidence, and confidence determines feasibility. Until off-target effects can be more fully characterized and controlled, safety will remain the dominant axis around which development strategies are organized.

The emergence of in vivo gene-editing therapies for lipid regulation carries implications that extend beyond technical feasibility into long-term clinical strategy. Because these interventions are designed to permanently alter gene expression, long-term follow-up becomes an integral component of development and deployment. Clinical programs have already incorporated extended observation periods to monitor durability and safety, with dedicated long-term follow-up studies planned for recipients of genome-editing therapies.²¹ This reflects an understanding that preventive interventions require evidence not only of short-term biomarker change but also of sustained biological stability.

At the strategic level, population genetics provides a foundation for rational target selection and risk stratification. Large-scale genetic studies demonstrating lifelong protection associated with specific loss-of-function variants offer a template for identifying which pathways are most likely to yield meaningful risk reduction when modified.^1,8 Rather than extrapolating from short-term pharmacologic effects, gene-editing strategies are grounded in inherited phenotypes that reflect decades of exposure.

This alignment supports a shift from treatment-centric to prevention-centric cardiovascular care. Instead of intervening after disease has progressed, gene editing aims to recalibrate baseline risk before clinical manifestations arise. In this model, therapy selection is informed by genetic architecture, enabling interventions to be matched to pathways with the strongest causal links to disease.

It is critical to view genome editing as a genetics-guided intervention strategy rather than a universal solution. Clinical implementation will depend on identifying populations most likely to benefit, defining acceptable risk thresholds for preventive use, and integrating long-term surveillance into standard care. As these elements coalesce, gene editing has the potential to redefine how cardiovascular risk is managed across the lifespan.

Despite rapid scientific progress, in vivo gene editing for cardiovascular risk reduction remains in an early clinical phase. Human data to date are limited to small, first-in-human studies with short follow-up periods, and conclusions about long-term benefit or safety cannot yet be drawn.^11,22 These initial results establish biological feasibility rather than population-level effectiveness, underscoring the distinction between proof-of-concept and a deployable public health intervention.

Recent experience has also highlighted the sensitivity of these programs to safety signals. Reported adverse events in early clinical testing have prompted enrollment pauses and regulatory review, reinforcing the need for cautious progression and rigorous oversight.^22,23 Such actions illustrate that even when genetic rationale is strong, translation into durable human benefit requires navigating unpredictable biological and clinical risk.

A central unresolved question is the balance between durability and reversibility. The defining feature of gene editing — permanent modification of gene expression — creates both its promise and its challenge. While lifelong suppression of a validated risk gene could theoretically provide sustained protection, permanence also limits the ability to adjust or withdraw therapy in response to unforeseen effects. This tension distinguishes gene editing from conventional lipid-lowering strategies, which allow for dose modulation and discontinuation over time.

Owing to these uncertainties, the current moment can be viewed as one of guarded optimism. Early studies demonstrate that genetic prevention is technically achievable, but they do not yet define the conditions under which it becomes clinically acceptable at scale. Moving from experimental intervention to public health strategy will depend on resolving questions of long-term safety, durability, and reversibility — issues that sit at the core of whether gene editing can fulfill its promise as a preventive modality rather than remain a narrowly applied innovation.

Decades of human genetic research have established that lifelong modulation of specific lipid-regulating genes can meaningfully reduce cardiovascular risk. Loss-of-function variants in targets such as PCSK9, APOC3, and LPA consistently associate with lower incidence of atherosclerotic disease, providing a biologically grounded rationale for intervention at the level of gene function rather than downstream pathology. These findings position genetics not as a risk marker alone but as a blueprint for prevention.

In vivo gene editing offers a direct mechanism to translate this blueprint into therapy. Early clinical programs targeting PCSK9 and ANGPTL3 demonstrate that precise genetic modification in the liver is technically feasible and can produce sustained changes in lipid biomarkers after a single intervention. While still in its infancy, this approach represents a structural shift in cardiovascular care from repeated pharmacologic suppression to permanent biological reprogramming.

At the same time, the path forward is defined by constraint as much as opportunity. The success of liver-directed delivery underscores how tightly feasibility is bound to organ accessibility, while unresolved questions around off-target effects and long-term safety continue to shape regulatory scrutiny. These limitations reinforce that gene editing is not yet a universal solution, but a modality whose application must be carefully aligned with risk tolerance and clinical context.

Taken together, these developments point toward an emerging paradigm of preventive cardiology grounded in genetics. Gene editing reframes cardiovascular risk as an engineering problem in which biology itself becomes the infrastructure for prevention. Whether this paradigm can extend beyond proof-of-concept to broad clinical impact will depend on the field’s ability to reconcile durability with safety, and innovation with restraint.

1. Cohen, Jonathan C, et al. “Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease.” NEJM. 354: 1264–1272 (2006).

2. “Transforming the Care of Cardiovascular Disease Through Single-course Gene Editing Medicines: Interim Results from heart-1 Trial of VERVE-101.” Verve Therapeutics. 12 Nov. 2023.

3. Dewey, Frederick E, et al. “Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.” NEJM. 377: 211–221 (2017).

4. Stitziel, Nathan O, et al. “ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.” J. Am. Coll. Cardiol. 69: 2054–2063 (2017).

5. Jørgensen, Anders Berg, et al. “Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease.” NEJM. 371: 32–41 (2014).

6. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. “Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease.” NEJM. 371: 22–31 (2014).

7. Gudbjartsson, Daniel F, et al. “Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes.” JACC. 9 Dec. 2019. https://www.jacc.org/doi/10.1016/j.jacc.2019.10.019

8. Emdin, Connor A, et al. “Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.” J. Am. Coll. Cardiol. 58: 2761–2772 (2016).

9. Doerfler, Alexandria M, et al. ”LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study.” Mol. Ther. Methods Clin. Dev. 27: 337–351 (2022).

10. NCT06164730: A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease. ClinicalTrials.gov. 17 Dec. 2025.

11. “VERVE-101: CRISPR-Based Gene Editing Therapy Shows Promise in Reducing LDL-C and PCSK9 Levels in Patients With HeFH.” American College of Cardiology. 12 Nov. 2023.

12. “A single infusion of a gene-editing medicine may control inherited high LDL cholesterol.” American Heart Association. 12 Nov. 2023.

13. NCT06451770: Phase 1 Study of VERVE-201 in Patients With Refractory Hyperlipidemia. ClinicalTrials.gov. 28 Nov. 2025.

14. Khera, Amit V. “An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise and durable liver editing in nonclinical studies.” EAS 92 Congress, Lyon, France. 28 May 2024.

15. NCT07176923: CS-121 APOC3 Base Editing in FCS. ClinicalTrials.gov. 16 Sep. 2025.

16. The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia. CorrectSequence Therapeutics. 5 Nov. 2025.

17. Chen, Kai, et al. “Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 ribonucleoprotein.” Nature Biotechnology. 43: 1445–1457 (2024).

18. Kasiewicz, Lisa N, et al. “GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy.” Nature Communications. 14: 2776 (2023).

19. Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry. U.S. Department of Health and Human Services. Jan. 2024.

20. Tavridou, Anna, et al. “Genome-editing medicinal products: the EMA perspective.” Nature Reviews Drug Discovery. 15 Mar. 2024.

21. NCT06112327: Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease. ClinicalTrials.gov. 27 Nov. 2024.

22. “Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels.” Reuters. 2 Apr. 2024.

23. Verve Therapeutics Announces Updates on its PCSK9 Program. Verve Therapeutics. 2 Apr. 2024. h